Clinical Trials Logo

Cytomegalovirus clinical trials

View clinical trials related to Cytomegalovirus.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05664126 Recruiting - Cytomegalovirus Clinical Trials

Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

The investigators want to learn if CMV- and ADV-specific T-cells (cells that fight infections) isolated (selected) from a donor using an automated medical device can be a safe treatment for treating patients with CMV, and ADV after transplant.This study will test the effects and safety of giving VSTs produced here at St. Jude in treating the participant's infection. Primary objective To determine the efficacy of VSTs to achieve a ≥1 log10 reduction in CMV and/or ADV viral load in the peripheral blood 4 weeks after VST infusion. When the initial viral load is <1 log10 above the threshold of detection, the objective is to achieve a reduction to below the threshold of detection. Secondary objectives - Determine the safety of VSTs when used to treat CMV and/or ADV viremia post-HCT. - Determine the proportion of patients who achieve a negative viral load at 3 months post-infusion. - Assess the persistence of response for 6 months post-infusion.

NCT ID: NCT03665675 Recruiting - Adenovirus Clinical Trials

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

Start date: November 7, 2020
Phase: Early Phase 1
Study type: Interventional

This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus [CMV] specific cytotoxic T-lymphocytes [CTLs]) or allogeneic adenovirus-specific cytotoxic T lymphocytes (donor adenovirus-specific [AdV] specific CTLs) work in treating CMV or AdV reactivation or infection in participants who have undergone stem cell transplant or solid organ transplant. White blood cells from donors may be able to kill cancer cells in patients with cytomegalovirus or adenovirus that has come back after a stem cell or solid organ transplant.

NCT ID: NCT01248598 Recruiting - Clinical trials for Epstein-Barr Virus Infections

The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis

Start date: October 2010
Phase: N/A
Study type: Observational

The purpose of this study is to study the prevalence of EBV, HCMV, HHV-6 in saliva and on the toothbrush patient with periodontitis.